Imaging of Recurrent Prostate Cancer

Radiologic Clinics of North America

Volumn 50, Issue 6, 2012, Pages 1075-1083

  Fütterer, Jurgen J ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Imaging; MRI; Multi parametric MRI; Prostate cancer; Recurrence

Indexed keywords

CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; WHOLE BODY MRI; WHOLE BODY SCINTISCANNING;

CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE; PROSTATIC NEOPLASMS; RECURRENCE; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

EID: 84868273348     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2012.08.005     Document Type: Review

References (54)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Djavan B., Moul J.W., Zlotta A., et al. PSA progression following radical prostatectomy and radiation therapy: new standards in the new millennium. Eur Urol 2003, 43:12-27.
3. Khan M.A., Han M., Partin A.W., et al. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 2003, 62:86-91. [discussion: 91-2].
4. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006, 24:3973-3978.
5. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
6. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294:433-439.
7. Jhaveri F.M., Zippe C.D., Klein E.A., et al. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999, 54:884-890.
8. Stanford J.L., Stephenson R.A., Coyle L.M., et al. Prostate cancer trends 1973-1995, SEER Program, National Cancer Institute 1999, NIH Pub, Bethesda (MD).
9. Vulto J.C., Lybeert M.L., Louwman M.W., et al. Population-based study of trends and variations in radiotherapy as part of primary treatment of cancer in the southern Netherlands between 1988 and 2006, with an emphasis on breast and rectal cancer. Int J Radiat Oncol Biol Phys 2009, 74:464-471.
10. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003, 95:981-989.
11. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233-1239.
12. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999, 281:1598-1604.
13. Jabbari S., Weinberg V.K., Shinohara K., et al. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 2010, 76:36-42.
14. Abramowitz M.C., Li T., Buyyounouski M.K., et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 2008, 112:55-60.
15. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
16. Horwitz E.M., Vicini F.A., Ziaja E.L., et al. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1998, 41:267-272.
17. Pound C.R., Brawer M.K., Partin A.W. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol 2001, 3:72-84.
18. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 2000, 163:1632-1642.
19. Stephenson A.J., Scardino P.T., Bianco F.J., et al. Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy. Curr Treat Options Oncol 2004, 5:357-365.
20. Catton C., Milosevic M., Warde P., et al. Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management. Urol Clin North Am 2003, 30:751-763.
21. Letran J.L., Brawer M.K. Management of radiation failure for localized prostate cancer. Prostate Cancer Prostatic Dis 1998, 1:119-127.
22. Crook J., Malone S., Perry G., et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000, 48:355-367.
23. Roehl K.A., Antenor J.A., Catalona W.J. Serial biopsy results in prostate cancer screening study. J Urol 2002, 167:2435-2439.
24. Pollack A., Zagars G.K., Antolak J.A., et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002, 54:677-685.
25. Barentsz J.O., Richenberg J., Clements R., et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22:746-757.
26. Stejskal E.O., Tanner J.E. Spin diffusion measurements: spin echoes in the presence of a time-dependent field-gradient. J Chem Phys 1965, 42:288-292.
27. Basser P.J., Mattiello J., LeBihan D. Estimation of the effective self-diffusion tensor from the NMR spin echo. J Magn Reson 1994, 103:247-254.
28. Collins D.J., Padhani A.R. Dynamic magnetic resonance imaging of tumor perfusion. IEEE Eng Med Biol Mag 2004, 23:65-83.
29. Wolf J.S., Cher M., Dall'era M., et al. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995, 153:993-999.
30. Hövels A.M., Heesakkers R.A., Adang E.M., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008, 63:387-395.
31. Hinkle G.H., Burgers J.K., Neal C.E., et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998, 83(4):739-747.
32. Picchio M., Messa C., Landoni C., et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]-fluorodeoxyglucose-positron emission tomography. J Urol 2003, 169:1337-1340.
33. de Jong I.J., Pruim J., Elsinga P.H., et al. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003, 44:32-38.
34. de Jong I.J., Pruim J., Elsinga P.H., et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003, 44:331-335.
35. Scattoni V., Picchio M., Suardi N., et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007, 52:423-429.
36. Kane C.J., Amling C.L., Johnstone P.A., et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003, 61:607-611.
37. Lentle B.C., McGowan D.G., Dierich H. Technetium-99M polyphosphate bone scanning in carcinoma of the prostate. Br J Urol 1974, 46:543-548.
38. Nakanishi K., Kobayashi M., Nakaguchi K., et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 2007, 6:147-155.
39. Sella T., Schwartz L.H., Swindle P.W., et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004, 231:379-385.
40. Pucar D., Hricak H., Shukla-Dave A., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007, 69:62-69.
41. Arrayeh E., Westphalen A.C., Kurhanewicz J., et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 2012, 82:787-793.
42. Sala E., Eberhardt S.C., Akin O., et al. Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 2006, 238:176-183.
43. Nguyen P.L., Whittington R., Koo S., et al. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59:400-405.
44. Kurhanewicz J., Vigneron D.B., Hricak H., et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 1996, 200:489-496.
45. Parivar F., Hricak H., Shinohara K., et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996, 48:594-599.
46. Coakley F.V., Teh H.S., Qayyum A., et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004, 233:441-448.
47. Pickett B., Kurhanewicz J., Coakley F., et al. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004, 60:1047-1055.
48. Pucar D., Shukla-Dave A., Hricak H., et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005, 236:545-553.
49. Zaider M., Zelefsky M.J., Lee E.K., et al. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2000, 47:1085-1096.
50. Haider M.A., Chung P., Sweet J., et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:425-430.
51. Rouvière O., Valette O., Grivolat S., et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-correlation with biopsy findings. Urology 2004, 63:922-927.
52. Sciarra A., Panebianco V., Salciccia S., et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008, 54:589-600.
53. Morgan V.A., Riches S.F., Giles S., et al. Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am J Roentgenol 2012, 198:596-602.
54. Kim C.K., Park B.K., Lee H.M. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 2009, 29:391-397.